In the future, analyses of circulating tumour DNA may enable the tracking of the response of subclinical disease to anti-HER2 with or without anti-ER treatment, and thereby aid both clinical management of patients and provide improved data for understanding the interaction of ER and HER2 signalling in patients. Here, ESR1 is linked to neoplasm.